OKYO Pharma shares are trading higher after the company's OK-101 achieved statistical significance for multiple signs and symptoms of dry eye disease in its first-in-human Phase 2 trial.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.